PL369472A1 - Kombinacja niesteroidowego leku przeciwzapalnego i inhibitora PDE-4 - Google Patents

Kombinacja niesteroidowego leku przeciwzapalnego i inhibitora PDE-4

Info

Publication number
PL369472A1
PL369472A1 PL02369472A PL36947202A PL369472A1 PL 369472 A1 PL369472 A1 PL 369472A1 PL 02369472 A PL02369472 A PL 02369472A PL 36947202 A PL36947202 A PL 36947202A PL 369472 A1 PL369472 A1 PL 369472A1
Authority
PL
Poland
Prior art keywords
combination
inhibitor
nsaid
pde
derivative
Prior art date
Application number
PL02369472A
Other languages
English (en)
Other versions
PL210463B1 (pl
Inventor
Thomas Klein
Hans-Peter Kley
Armin Hatzelmann
Manfrid Eltze
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of PL369472A1 publication Critical patent/PL369472A1/pl
Publication of PL210463B1 publication Critical patent/PL210463B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PL369472A 2001-09-19 2002-09-17 Zastosowanie kombinacji roflumilastu z diklofenakiem w leczeniu zapalnych chorób stawów PL210463B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01000473 2001-09-19

Publications (2)

Publication Number Publication Date
PL369472A1 true PL369472A1 (pl) 2005-04-18
PL210463B1 PL210463B1 (pl) 2012-01-31

Family

ID=8176065

Family Applications (1)

Application Number Title Priority Date Filing Date
PL369472A PL210463B1 (pl) 2001-09-19 2002-09-17 Zastosowanie kombinacji roflumilastu z diklofenakiem w leczeniu zapalnych chorób stawów

Country Status (25)

Country Link
US (2) US20040242597A1 (pl)
EP (1) EP1429807B1 (pl)
JP (1) JP4588998B2 (pl)
KR (1) KR100949528B1 (pl)
CN (1) CN100496607C (pl)
AT (1) ATE355080T1 (pl)
AU (1) AU2002337105B2 (pl)
BR (1) BR0212606A (pl)
CA (1) CA2459757C (pl)
CY (1) CY1108011T1 (pl)
DE (1) DE60218497T2 (pl)
DK (1) DK1429807T3 (pl)
EA (1) EA008108B1 (pl)
ES (1) ES2282469T3 (pl)
HK (1) HK1066730A1 (pl)
HU (1) HU229442B1 (pl)
IL (2) IL160271A0 (pl)
MX (1) MXPA04002562A (pl)
NO (1) NO331756B1 (pl)
NZ (1) NZ532278A (pl)
PL (1) PL210463B1 (pl)
PT (1) PT1429807E (pl)
SI (1) SI1429807T1 (pl)
WO (1) WO2003024489A2 (pl)
ZA (1) ZA200402654B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110424A1 (en) * 2003-05-28 2004-12-23 Glaxo Group Limited Method and pharmaceutical formulation for reducing stress-induced accelerated colonic transit in a mammal
CA2534316A1 (en) * 2003-08-07 2005-02-24 B.M.R.A. Corporation B.V. Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxygenase-1
JP2007509154A (ja) * 2003-10-21 2007-04-12 ファルマシア・コーポレーション ホスホジエステラーゼ４阻害剤と組み合わせたシクロオキシゲナーゼ−２阻害剤による呼吸器炎症のの治療または予防のための方法およびその組成物
EP1683521A1 (en) * 2005-01-21 2006-07-26 Centre National De La Recherche Scientifique (Cnrs) Peptide deformylase inhibitors, their use, and pharmaceutical compositions containing the same
EP1688413A1 (en) * 2005-02-03 2006-08-09 Hikma Pharmaceuticals Co. Ltd. Benzoxazole derivatives for the prophylaxis and treatment of inflammatory bowel diseases
JP2008533090A (ja) * 2005-03-14 2008-08-21 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 心血管疾患の防止方法
CA2611907A1 (en) * 2005-06-17 2006-12-21 Boehringer Ingelheim International Gmbh Mrp iv inhibitors for the treatment of respiratory diseases
CN101426485B (zh) * 2006-04-28 2013-02-13 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
FR2909876A1 (fr) * 2006-12-19 2008-06-20 Galderma Res & Dev S N C Snc Utilisation du nepafenac ou ses derives pour le traitement de desordres dermatologiques
KR101709141B1 (ko) 2008-01-25 2017-02-22 브이티브이 테라퓨틱스 엘엘씨 ＴＮＦ-α 합성의 조절자 및 ＰＤＥ4 억제제로서 3고리 화합물
CA2716799C (en) * 2008-03-04 2018-05-22 Pfizer Limited Methods of treating inflammatory pain
US8592400B2 (en) 2009-02-27 2013-11-26 Boehringer Ingelheim International Gmbh Drug combinations containing PDE4 inhibitors and NSAIDs
CA2753604A1 (en) 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Drug combinations containing pde4-inhibitors and nsaids
AP2015008663A0 (en) 2013-02-19 2015-08-31 Pfizer Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of cns and other disorders
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
CU20170007A7 (es) 2014-08-06 2017-06-05 Pfizer Compuestos de imidazopiridazina
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20230017266A1 (en) * 2019-12-03 2023-01-19 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Cyclooxygenase-2 Inhibition for the Treatment of SAA-high Asthma
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2023049809A1 (en) * 2021-09-22 2023-03-30 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
GB2228736A (en) 1989-02-10 1990-09-05 Sterivet Lab Ltd Cosmetic formulation
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
JP2001521926A (ja) 1997-11-04 2001-11-13 ファイザー・プロダクツ・インク 治療上活性の化合物におけるカテコールのインダゾール生物学的等価物置換
AU5873000A (en) 1999-06-24 2001-01-31 Pharmacia Corporation Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors forthe treatment of inflammation
JP5038568B2 (ja) * 1999-08-21 2012-10-03 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 協力剤の組合せ物
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
AR029189A1 (es) * 1999-11-02 2003-06-18 Smithkline Beecham Corp Uso de un inhibidor de fosfodiesterasa 4 y un corticoesteroide antiinflamatorio en forma combinada, separadamente o separadamente secuencial para la preparacion de un medicamento
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6372777B1 (en) * 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
BR0107964A (pt) * 2000-01-31 2002-10-29 Pfizer Prod Inc Derivados de nicotinamida benzofundida com heterociclica úteis como inibidores seletivos de isozimas pde4
CA2398184A1 (en) * 2000-02-08 2001-08-16 Smithkline Beecham Corporation Method and compositions for treating an inflammatory disease
ATE305467T1 (de) * 2001-01-31 2005-10-15 Pfizer Prod Inc Als inhibitoren von pde4-isozymen geeignete etherderivate
EA200300836A1 (ru) * 2001-02-15 2004-02-26 Алтана Фарма Аг Производные фталазинон-пиперидина в качестве ингибиторов pde4

Also Published As

Publication number Publication date
HUP0401582A3 (en) 2008-04-28
KR100949528B1 (ko) 2010-03-25
CA2459757C (en) 2011-08-30
MXPA04002562A (es) 2004-05-31
DE60218497T2 (de) 2007-11-08
WO2003024489A2 (en) 2003-03-27
KR20040053129A (ko) 2004-06-23
IL160271A0 (en) 2004-07-25
PL210463B1 (pl) 2012-01-31
EP1429807B1 (en) 2007-02-28
NO331756B1 (no) 2012-03-19
WO2003024489A3 (en) 2003-09-18
JP2005504077A (ja) 2005-02-10
US20080255209A1 (en) 2008-10-16
AU2002337105B2 (en) 2008-03-20
EP1429807A2 (en) 2004-06-23
PT1429807E (pt) 2007-05-31
US8242146B2 (en) 2012-08-14
HU229442B1 (hu) 2013-12-30
ZA200402654B (en) 2005-04-26
CA2459757A1 (en) 2003-03-27
CY1108011T1 (el) 2013-09-04
ATE355080T1 (de) 2006-03-15
EA008108B1 (ru) 2007-04-27
DK1429807T3 (da) 2007-06-18
JP4588998B2 (ja) 2010-12-01
HUP0401582A2 (hu) 2004-11-29
BR0212606A (pt) 2004-08-17
US20040242597A1 (en) 2004-12-02
HK1066730A1 (en) 2005-04-01
SI1429807T1 (sl) 2007-08-31
CN100496607C (zh) 2009-06-10
NZ532278A (en) 2006-02-24
ES2282469T3 (es) 2007-10-16
CN1625411A (zh) 2005-06-08
IL160271A (en) 2008-03-20
EA200400410A1 (ru) 2004-12-30
NO20041596L (no) 2004-06-18
DE60218497D1 (de) 2007-04-12

Similar Documents

Publication Publication Date Title
HK1066730A1 (en) Combination of a nsaid and a pde-4 inhibitor
BRPI0411825A (pt) inibidores de p38 quinase a base de heterociclo de 5 elementos
WO2002085342A3 (en) Use of nsaids for prevention and treatment of cellular abnormalities of the lung or bronchial pathway
AU2003206785A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
CY1108274T1 (el) Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
EP1900362A3 (en) Alfa-aminoamide derivatives useful in the treatment of addictive disorders
MXPA04001088A (es) Derivados de pirazol como inhibidores de cinasa y uso de los mismos.
CY1109529T1 (el) 2-(αμινο-υποκατεστημενες)-4-αρυλο πυραμιδινες και σχετικες ενωσεις που χρησιμευουν στην αγωγη φλεγμονωδων νοσηματων
WO2004093803A3 (en) Photochemotherapeutic compounds for use in treatment of pin1-associated states
IL186374A0 (en) Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
UA85711C2 (ru) Замещенные енаминоны, их производные и их применение
EA200200875A1 (ru) Пролекарства производных имидазопиридина
SE9802794D0 (sv) New compounds
SE9802793D0 (sv) New compounds
WO2006014468A3 (en) Saif, an anti-inflammatory factor, and methods of use thereof
MX2008011508A (es) El uso de beta-aminoalcoholes para el tratamiento de desordenes inflamatorios y dolor.
EE05263B1 (et) IL-18 inhibiitorite kasutamine keskn„rvissteemi kahjustuste raviks v?i ennetamiseks
AR045724A1 (es) Composicion farmaceutica orodispersable de un compuesto antitrombotico
MXPA03009506A (es) USO DE COMPUESTOS ELIMINADORES DE RADICALES PARA EL TRATAMIENTO Y PREVENCIoN DE TRASTORNOS DE LA MICRO-CIRCULACION DEPENDIENTES DE NO.
MY141010A (en) Use of ppar agonists for the treatment of congestive heart failure